



GCOM 2024 Program outline

Check online for updates: <https://gcom.imyos.org/>

Wednesday, March 13

9:00-9:30 Welcome and Introduction

9:30-11:00 Pathogenesis of Inflammatory Myopathies: Transcriptomic Analyses

Co-Chairs: Andrew Mammen, Jessica Neely

- 20 minutes: Muscle Transcriptomics in IIM- Iago Pinal-Fernandez (NIH, USA)
- 20 minutes: Muscle Transcriptomics in JDM - Jessica Turnier (University of Michigan, USA)
- 20 minutes: Peripheral Blood Transcriptomics - Karine Chemine (Karolinska Institutet, Sweden)
- 30 minutes: Selected oral presentations

11:00-11:15 Break

11:15-13:00 Genetic/Environmental

Co- Chairs: M. Needham; Adam Schiffenbauer (NIH, USA)

- 15 minutes: Immunostimulatory effects of herbal supplements on autoimmune disease - Deanna Diaz (Rutgers, USA)
- 15 minutes: Genetic risk factors in IIM - Janine Lamb (Manchester, UK)
- 45 minutes: COVID-19
 - Safety of COVID-19 vaccination in RD - COVAX Registry - Pedro Machado (UCL, UK)
 - COVID-19 vaccination outcomes among DM patients - Latika Gupta (Manchester, UK)
 - Neuromuscular complications of COVID-19 - Joome Suh (Harvard, USA)
- 30 minutes: Selected oral presentations

13:00-14:30 Lunch—Industry Symposia

14:30-16:20 Inclusion Body Myositis

Co-Chairs: Tony Amato (Harvard, USA); Vladimir Liarski (U. Pittsburgh, USA)

- 20 minutes: Current State of IBM - Merrilee Needham (Australia)
- 15 minutes: Disease models of IBM and their therapeutic implications - Tom Lloyd (Baylor, USA)
- 15 minutes: Single-nucleus RNA sequencing in IBM - Christopher Nelke (Universitätsklinikum Düsseldorf, Germany)
- 30 minutes: Mimics of IBM
 - Clinical Mimics of IBM - Elie Naddaf (Mayo Clinic, USA)
 - Morphological Mimics of IBM - Werner Stenzel (Charité Universitätsmedizin, Germany)
- 30 minutes: Selected oral presentations

16:20-16:45 Break

16:45-18:30 IIM Classification: Different Perspectives

Co-Chairs: Didem Saygin, Ingrid Lundberg

- 15 minutes: European Neuromuscular Centre Workshop for IBM - James Lilleker (Manchester, UK)
- 15 minutes: European Neuromuscular Centre Workshop for Dermatomyositis, Immune Mediated Necrotizing Myositis, and Anti-Synthetase Syndrome – Yves Allenbach (Sorbonne Université, France)
- 15 minutes: Pathologic Classification of IIM - Jantima Tanboon (Mahidol University, Thailand)
- 15 minutes: Classification of Overlap Myositis - Oceane Landon-Cardinal (Université de Montréal, Canada)
- 15 minutes: CLASS Project Update - Giovanni Zanframundo (University of Pavia, Italy)
- 30 minutes: Panel Discussion with audience participation (Moderators: Didem Saygin and Ingrid Lundberg)

18:30-20:30 Cocktails/Dinner and Keynote Lecture: CAR-T Cell Therapy: “The Future is Now” – Georg Schett (FAU Erlangen-Nürnberg, Germany)

Thursday, March 14

8:00-8:30 iMyoS and future GCOM meetings

8:30-10:15 Advances in Therapeutic Development

Co-Chairs: Chet Oddis (U. Pittsburgh, USA); Annet Royen-Kerkhof (U. Utrecht, Netherlands)

- 30 minutes: Therapeutic Targeting of Immunopathogenic Pathways in Myositis
 - Femke van Wijk (Utrecht University, Netherlands)
 - David Fiorentino (Stanford)
- 30 minutes: Geographic differences in treatment of MA-ILD: North American vs. Asian perspective
 - North American Perspective - Erin Wilfong (Vanderbilt Univ. Medical Center, USA)
 - Asian Perspective - Takahisa Gono (Nippon Medical School, Japan)
- 15 minutes: Advances in exercise and medical therapies – focus on JDM - Susan Maillard (University College London, UK)
- 30 minutes: Selected oral presentations

10:15-11:15 Break and Poster Session-1

11:15-12:35 Juvenile Myositis: Promising Avenues for New Therapies

Co-Chairs: Lucy Wedderburn, Christian Lood (Jessica Turnier)

- 20 minutes: State of art review on biomarkers and novel therapeutics for juvenile myositis – Hannah Kim (NIH, USA)
- 15 minutes: Intersection of IFN and mitochondrial changes in juvenile myositis - Meredith Wilkinson (University College London, UK)
- 15 minutes: Sodium thiosulfate for treatment of calcinosis in dermatomyositis: Trial results - Adam Schiffenbauer (NIH, USA)
- 30 minutes: Selected oral presentations

12:45-14:00 Lunch—Patient Support Organizations

14:00-15:50 Clinical Trials

Co-chairs: Susan Kim (University of California, San Francisco, USA), Julie Paik (Johns Hopkins, USA)

- 20 minutes: Evaluating ILD as a key outcome in IIM Trials - Sonye Danoff (Johns Hopkins, USA)
- 20 minutes: Skin endpoints/outcomes in clinical trials - Vicky Werth (University of Pennsylvania, USA)

- 20 minutes: Adaptive clinical trials – The REMAP-CAP Experience - Bryan McVerry (University of Pittsburgh, USA)
- 20 minutes: Issues and Challenges in Clinical Trial Design - Rohit Aggarwal (University of Pittsburgh, USA)
- 30 minutes: Selected oral presentations

15:50-16:15 Break**16:15-18:00 Workshop Session-1A and 1B**

- **Pathology Workshop:**

- Tony Amato (Brigham & Women's Hospital, USA)
- Anne Schänzer (Justus-Liebig University, Gießen, Germany)
- Alan Pestronk (Washington University in St. Louis, USA)
- Ichizo Nishino (National Institute of Neuroscience, Japan)
- Dave Lacomis (University of Pittsburgh, USA)

This session will review topics relevant to different histopathologic subtypes of myositis, standardization of IHC protocols, impact of biopsy method on histopathologic analyses, and inter-rater reliability of histopathology interpretation.

- **Disease Models Workshop:**

- Lauren Covert (Duke University, USA) - Human skeletal muscle model of juvenile dermatomyositis
- Olivier Boyer (CHU Rouen Normandie, France)— antibody mediated HMGC_oA reductase model
- Naoko Okiyama (Tokyo Medical and Dental University, Japan)—cell mediated TIF1 γ model

Session highlights will include discussion of both in vitro and in vivo model systems that can help to advance our knowledge of myositis immunopathogenesis.

18:30-22:00 Dinner and Group Activity

Friday, March 15

8:30-10:10 Extramuscular manifestations

Co-chairs: Anthony Fernandez (Cleveland Clinic), Daniel Kass (University of Pittsburgh)

- 20 minutes: When ILD goes bad - Rob Hallowell (Massachusetts General Hospital, USA)
- 40 minutes: Approach to management of skin disease
 - 20 minutes: Topical Immunosuppression - Michelle Min (UC Irvine, USA)
 - 20 minutes: Clinical presentation and dermatopathology - Alisa Femia (New York University, USA)
- 20 minutes: Dysphagia in IIM – Kendrea Garand (University of Pittsburgh, USA)--role of speech pathology
- 20 minutes: Prediction models of IIM-ILD - Cheilonda Johnson (University of Pennsylvania, USA)

10:10-11:15 Break and Poster Session-2

11:15-12:45 Workshop Session-2A and 2B

- **Autoantibody Workshop:**
 - Jean-Baptiste Vulsteke (KU Leuven, Belgium) - Autoantibody discovery
 - Ingrid Lundberg (Karolinska Institutet, Sweden) & Dana Ascherman (University of Pittsburgh, USA) - Epitope profiling and phenotype
 - Sarah Tansley (University of Bath, UK) – Reliability of various methodologies

This session will review advances in the methodology of autoantibody detection, the recent discovery of novel autoantibodies, and the relationship between autoantibody epitope profile and clinical phenotype.

- **Exercise and Rehabilitation:**
 - Helene Alexanderson (Karolinska Institutet, Sweden) - Practical approach to exercise
 - Yasser Salem (Hofstra University, USA) - Advancements in rehabilitation

The focus of this session will be on advancements in rehabilitation methods and practical implementation of exercise therapy.

12:45-14:30 Lunch and Speed Funding Competition

14:30-16:15 Potpourri

Co-chairs: Dana Ascherman (University of Pittsburgh, USA), Erin Wilfong (Vanderbilt University Medical Center, USA)

- 30 Minutes: Plenary: Funding overview for early and established investigators through NIH – Lindsey Criswell (NIH, USA)
- 45 minutes: Exercise & Rehabilitation
 - Exercise and Inflammation - Helene Alexanderson (Karolinska Institute, Sweden)
 - Physiological and Psychological Impact of Exercise - Kristofer M. Andreasson (Karolinska Institutet, Sweden)
- 30 Minutes: Patient Support Organizations: Helping Patients Heal — TMA, Cure JM, UK Myositis

16:15-17:15 Break and Poster Session-3

17:15-18:15 Roundtable Governance Discussion: Integration/coordination of myositis-related programming and objectives.

- **Moderator:** Fred Miller
- **Panelists:** Lisa Rider (IMACS), Lesley Saketkoo (MIHRA), Hector Chinoy (MyoNet), Jens Schmidt (iMyoS), Rohit Aggarwal (MCTC), Susan Kim (CARRA), Meredyth Wilkinson (PReS JDM)

18:30-19:30 SIGs (IMACS)

19:30-21:00 Dinner

21:00-?? Social Activity (Drinks/Music)

Saturday, March 16

8:00-9:45 Imaging as a Biomarker

Co-Chairs: Myma Albyda (Johns Hopkins, USA), Pedro Machado (University College London, UK)

- 15 minutes: European Neuromuscular Centre Imaging Summary - Marianne de Visser (University of Amsterdam, Netherlands)
- 15 minutes: MRI - Andrea Doria (Hospital for Sick Children, University of Toronto, Canada)
- 15 minutes: Capillaroscopy - Thaisa Cotton (McGill University, Canada)
- 15 minutes: Immune Cell Imaging - Colin Quinn (University of Pennsylvania, USA)
- 15 minutes: Ultrasound - Christiaan Saris (Radboud Universiteit, Netherlands)
- 30 minutes: Selected oral presentation

9:45-10:00 Break

10:00-11:30 Malignancy

Co-chairs: Hector Chinoy (University of Manchester, UK), Siamak Moghadam-Kia (University of Pittsburgh)

- 20 minutes: Cancer screening in idiopathic inflammatory myopathies.. where do we go from here – Alex Oldroyd (University of Manchester, UK)
- 25 minutes: Management of new/existing dermatomyositis needing immune checkpoint inhibitor therapy – Nicole LeBoeuf and Katharina Shaw (Brigham & Women’s Hospital, USA)
- 45 minutes: Selected oral abstracts

11:30-12:00 Closing Remarks

ADJOURN